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Therapy of Mycosis Fungoides 
Harvey G. Shapero, M.D.* 
Mycosis fungoides is best viewed as a cutaneous lymphoma. Over a period of 
years, it progresses through three stages—the first consisting of red scaly patches, 
the second of pruritic plaques, and the third of brownish-red tumors. The therapy 
of each stage is outlined, and several selected modalities are discussed in detail, 
including topical steroids, systemic steroids, localized superficial irradiation, topical 
nitrogen mustard, electron beam, and chemotherapy (alkylating agents and anti-
metabolites). 
Mycosis fungoides (MF) is a pruri-
tic cutaneous disorder best classified as 
a form of lymphoma. It is known for 
its steady progression interrupted by 
temporary remissions induced by 
therapy. Its course is long and usually 
continues over many years before death 
occurs. Clinically, it presents in three 
stages, each of which merits a different 
therapeutic approach:' -
Stage I —Premycotic stage (erythe-
matous, eczematous stage) 
Stage I I —Plaque stage (infiltrative 
stage) 
Stage I I I —Tumor stage. 
The premycotic stage is character-
ized by scaly erythematous patches 
which may be very pruritic. This stage 
may bear a strong clinical resemblance 
to nonspecific dermatitis, psoriasis or 
parapsoriasis. In the plaque stage, ir-
regular but circumscribed areas of 
thickening and induration occur. 
Brownish red skin tumors which often 
ulcerate are the hallmark of the tumor 
stage. Many patients eventually de-
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velop visceral involvement, most com-
monly the lymph nodes, but also the 
spleen, liver, kidney, gastrointestinal 
tract or other organs. Symptoms such 
as fever, weight loss and anemia may 
indicate late disease with visceral in-
volvement. Once stage I I I is reached, 
survival is usually less than 2-3 years.''•^  
Thorough clinical and laboratory eval-
uation is therefore mandatory. This 
should include hematological consulta-
tion with examination of peripheral 
blood and bone marrow. Lymphangio-
graphy, chest X-ray, liver scan, and 
tests of liver and kidney function are 
also valuable. 
In contrast to other malignancies 
where early aggressive therapy offers 
the best chance of cure, most investi-
gators"'-^  currently recommend a con-
servative therapeutic approach, real-
izing that therapy is only palliative and 
that the disease even untreated may 
progress very slowly. A notable excep-
tion, however, is Van Scott^  who states: 
"There are compelling reasons why 
early treatment of M.F. should be 
vigorously pursued . . . postponement 
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OUTLINE OF THERAPY 
STAGE I (scaly red patches) 
L Symptomatic 
(Compresses, baths, emollients,, antipruritics and antibiotics as 
necessary for secondary infection) 
2. Topical steroids 
(With or without occlusion) 
3. Ultraviolet light 
4. Grenz irradiation 
5. Topical nitrogen mustard 
STAGE II (thickened plaques) 
L Measures as for Stage I 
(Intralesional steroids may be beneficial for small nodules or plaques) 
2. Ionizing irradiation 
(Except for Grenz, limited to patients not readily responsive to above) 
a. Superficial x-ray (local lesions) 
b. Electron beam (widespread lesions) 
Lesions not responding to the above, may be treated as for Stage III. 
STAGE III (tumors) 
A. When not rapidly progressive 
L Measures outlined previously 
B. When escapes from control 
1. Local superficial irradiation 
2. Electron beam "i If previous measures fail, or 
3. Systemic chemotherapy / if lesions are extensive. 
C. Internal involvement 
1. Systemic chemotherapy ( t radiation). 
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Figure 1 
Erythematous scaly eruption of stage I . 
Shapero 
Figure 2 
Thickened plaques of stage I I . 
Figure 3 
Cutaneous tumors of Stage I I I . 
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of aggressive therapy until later stages 
of the disease occurs, limits the final 
choice to chemotherapeutic drugs . . ." 
Topical Steroids 
Beneficial effects on MF have been 
reported with systemic steroids, intra-
lesional steroids in infiltrated lesions 
and topical steroids. Farber treated 20 
patients with varying concentrations of 
fluocinolone acetonide cream (0.01%, 
0.025%, 0.2% and 1.0%). He found 
suppression of early and moderately 
advanced lesions with 0.2% and 1.0% 
concentrations. However, and more im-
portantly, he found that continued ap-
plications of even 0.01% produced re-
missions lasting three months or longer 
in some patients, when plastic film oc-
clusion technique was used at least 12 
hours daily. In deeply infiltrated le-
sions, only 50% improvement was 
noted even with 0.2%. Subsequent 
intralesional triamcinolone acetonide 
gave good results in these sites (5 mgs/ 
cc—about 1 cc per lesion).* 
Systemic Steroids 
Systemic steroids are occasionally 
used in late disease, in two instances. 
The first is in high dosage for a short 
term in which results are short lived. 
It may be useful symptomatically while 
another agent such as radiation or 
chemotherapy is taking effect. The sec-
ond is in chronic low dosage in com-
bination with radiation or chemother-
apy if the response to these latter meas-
ures is only partial. Bluefarb feels that 
steroids should be reserved for patients 
who are debilitated or who have throm-
bocytopenia or hemolytic anemia. The 
dosage should be minimal.' 
Local Superficial Irradiation 
This is useful when the number of 
lesions are few. Recurrence is the rule, 
but re-treatment usually can be em-
ployed successfully. Bluefarb recom-
mends 60-100 KV, 3-5 MA, 15-20 cm 
FSD and a HVL of 1.0-1.5 mm alum-
inum." The sites are screened off to 
include a border (0.5-2 cm) of normal 
skin. Treatments can be given weekly. 
MF lesions are radio-sensitive, and 
often as little as 150-300r will be ef-
fective. 
Grenz therapy, a very superficial 
form of irradiation, may offer sympto-
matic relief in early disease. Ultraviolet 
light may also be helpful in early MF. 
Topical Nitrogen Mustard 
(mechlorethamine HCl) 
The method consists of adding 10 
mgs of nitrogen mustard (NM) to 50 
cc saline or room-temperature tap 
water. This must be used immediately 
after mixing, as it degrades readily. The 
skin cleansed of all greases and 
ointments. Wearing rubber gloves, the 
physician or nurse paints the entire 
skin with small gauze squares held with 
a hemostat. Precautions must be taken 
to avoid direct contact with the un-
diluted mixture, especially by the eyes 
or mucous membranes. The skin is kept 
moist for 15 minutes and the entire 
50 cc is used. The skin may be dried 
with a towel or allowed to air dry. A 
soap-and-water bath is taken three 
hours later to remove NM degradation 
products. 
NM may be applied daily for one 
week, then once weekly or as necessary 
for maintenance. If allergic contact 
dermatitis develops, therapy can still 
be continued but with a more dilute 
solution, such that only erythema and 
induration occurs. 
No side effects have been reported 
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except for allergic contact sensitiza-
tion'-^'i" and some cutaneous pigmen-
tation with continued use. No evidence 
of systemic toxicity has been shown 
such as nausea, diarrhea, ulcers or 
bone marrow depression. In fact, there 
has been no evidence of any significant 
systemic absorption.' Uninvolved areas 
of skin are not affected. Allergic contact 
dermatitis has been reported in 4 of 29 
cases,in 0 of 50 cases,and in 1 of 
11 cases.^  Van Scott reported contact 
dermatitis in 6 of 21 cases,'^  but he used 
somewhat higher concentrations of 
NM. 
Results have been encouraging. 
Roenigk and Haserick report favor-
able results in all of 50 cases to varying 
degrees, both clinically and histologi-
cally. Pruritus disappeared early. They 
emphasize that topical nitrogen mus-
tard is not a cure but it induces remis-
sion." Arundell reports that all of her 
11 patients showed improvement in 4 
weeks or less." Van Scott reports com-
plete remission of plaque stage MF 
in a majority of his patients. Resolu-
tion of tumors is also reported with 
intradermal injection, but not with 
topical NM in this stage of the disease." 
Most investigators do not recom-
mend topical NM for the tumor stage 
of MF. A recent report, however, tells 
of 11 patients with recurrence subse-
quent to electron beam therapy in all 
of whom pruritus disappeared within 
one week and ulcers and plaques im-
proved or disappeared in 2-4 weeks." 
Van Scott recently noted the most 
rapid clearing of clinical lesions in pa-
tients who became sensitized to N M . ' 
In an earlier paper,i- the majority of 
MF lesions, in six patients sensitized 
to DNCB (dinitrochlorobenzene) and 
AET (aminoethylthiuronium), cleared 
when the patients were treated topical-
ly with these substances to produce de-
layed hypersensitivity reactions. These 
agents were chosen only because they 
are potent sensitizers. He notes the 
normal ability of MF patients to pro-
duce both circulating antibodies and to 
develop delayed hypersensitivity. This 
contrasts with the impaired delayed 
reaction observed with other lympho-
mas. He also notes that the initial 
process of MF is identified by an infil-
trate predominantly of normal lympho-
reticular cells (the same cells commonly 
associated with delayed sensitivity). 
Only later do abnormal cells emerge 
in abundance. He suggests the possi-
bility that early MF may be a cellular 
reaction to some unknown stimulus. 
Madison and Haserick reported on 
12 dermatoses treated topically with 
N M . " They found improvement in 
MF, Hodgkin's disease of the skin and 
in Bowen's disease; temporary im-
provement in parapsoriasis en plaque, 
and no improvement in lichen planus, 
plantar warts, seborrheic dermatitis and 
Sezary's syndrome. Resolution of pso-
riatic skin lesions, using topical NM, 
was recently demonstrated in seven pa-
tients. 
Electron Beam 
Low megavolt electron beam therapy 
(1.5-2.5 mev) can be very helpful for 
extensive disease when whole body ir-
radiation is desired. 200 rads every day 
to a total of 600-800 rads are recom-
mended. When many lesions are pres-
ent (ie, multiple scattered plaques) local 
regular superficial x-ray is cumber-
some and hazardous because of mar-
row depression. It is here that electron 
beam therapy is most useful. Therapy 
can be given to the entire body surface 
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since the major ionizmg effect is only 
1-2 mm in depth and the maximal 
penetration 1 cm. Lesions thicker than 
1 cm can be treated subsequently by 
conventional x-ray. Very advanced 
cases can be treated with concomitant 
chemotherapy. Responses are good; re-
missions vary from weeks to months. 
Electron beam therapy can be repeated 
several times at 3-6 month intervals. 
The best review of this mode of 
therapy is a nine-year follow-up of 200 
cases from the Massachusetts Institute 
of Technology and the Lahey Clinic.^ 
They conclude that desperately il l pa-
tients can be salvaged for many months 
beyond the natural course of advanced 
disease. 
Chemotherapy 
Chemotherapy is clearly indicated 
when systemic manifestations are pres-
ent. It may also be employed in stage 
I I I disease and in extensive stage I I 
when other measures fail. Irradiation 
may be administered concomitantly. 
The drugs frequently used are the al-
kylating agents and antimetabolites.-'^'® 
Alkylating Agents 
Nitrogen mustard may be given ui-
travenously. If used for long-term 
maintenance therapy, it should be used 
with caution because of hematopoietic 
toxicity. 
Oral agents that have been used 
successfully include cyclophosphamide 
(Cytoxan—1-3 mgs/kg daily) and 
chlorambucil (Leukeran—0.1-0.2 mgs 
/kg daily). Although these may be used 
for long-term therapy, some prefer in-
termittent therapy to offset toxic ef-
fects, such as a course over 4-6 weeks. 
Approximately 50% of patients show 
objective improvement. 
Bluefarb considers cyclophospha-
mide his first choice among chemo-
therapeutic agents for MF. He gives 
in the hospital 200 mgs daily IV by 
slow drip, then 50 mgs daily orally.' 
Antimetabolites 
1. Methotrexate appears promising 
but experience with it in MF is still 
limited. It has been found that the in-
filtrate of MF is relatively slow-
growing; therefore, weekly methotrex-
ate (50 mgs) can be successfully em-
ployed. If lesions tend to regain their 
size before the next dose, 25 mgs twice 
weekly is recommended, but only when 
a weekly regimen is ineffective, since 
more toxicity can be anticipated. Over 
half of a group of patients showed 
50% regression with this regimen. Six 
of 30 showed complete remissions for 
5-20 months.® Careful attention must 
be paid to pretreatment and followup 
of hepatic, renal and hematopoietic 
functions. 
2. Triacetyl azauridine has also 
been reported to give beneficial re-
sults." 
Summary 
Mycosis fungoides is a slowly pro-
gressive cutaneous lymphoma which is 
often complicated by visceral involve-
ment. Thorough diagnostic investiga-
tion is therefore imperative, especially 
in late disease. This should include 
hematological evaluation, liver and kid-
ney function tests and diagnostic x-rays 
including lymphangiography. The eti-
ology is unknown and^ there is no spe-
cific cure. There are, however, a num-
ber of measures that offer prolonged 
remissions and substantial symptomatic 
relief. In early disease, these include 
general symptomatic care, topical ster-
oids, ultraviolet light, Grenz irradiation 
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and topical nitrogen mustard. Later, useful chemotherapeutic compounds 
superficial x-ray and electron beam are the alkylating agents and antime-
therapy are helpful. When visceral in- tabolites. Because of the chronic pro-
volvement is detected, systemic chemo- gressive nature of the disease, suppor-
therapy becomes necessary. The most tive psychotherapy is valuable. 
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